# A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

> **NCT03248492** · PHASE2 · TERMINATED · sponsor: **Daiichi Sankyo** · enrollment: 253 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** DS-8201a

## Key facts

- **NCT ID:** NCT03248492
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-25
- **Primary completion:** 2019-03-21
- **Final completion:** 2024-05-06
- **Target enrollment:** 253 (ACTUAL)
- **Why stopped:** The last participant was transitioned to alternative study.
- **Last updated:** 2025-06-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03248492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03248492, "A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03248492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*